Nonalcoholic steatohepatitis (NASH)
Clinical trials for Nonalcoholic steatohepatitis (NASH) explained in plain language.
Never miss a new study
Get alerted when new Nonalcoholic steatohepatitis (NASH) trials appear
Sign up with your email to follow new studies for Nonalcoholic steatohepatitis (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to melt liver fat in NASH patients
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase 2 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Needle-Free scans could spot silent liver damage
Diagnosis Recruiting nowNonalcoholic fatty liver disease affects many people with obesity or type 2 diabetes, and its more serious form, nonalcoholic steatohepatitis, can lead to cirrhosis and liver failure. Doctors currently rely on liver biopsy to judge how severe the disease is, but that test is inva…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase 1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC